{
    "clinical_study": {
        "@rank": "8089", 
        "arm_group": [
            {
                "arm_group_label": "Afalaza (2 tablets twice a day)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo (2 tablets twice a day)", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is:\n\n        -  To assess safety of Afalaza drug within 12 months in patients with symptoms of benign\n           prostatic hyperplasia and risk of progression.\n\n        -  To assess efficiency of Afalaza drug within 12 months in patients with symptoms of\n           benign prostatic hyperplasia and risk of progression."
        }, 
        "brief_title": "Clinical Trial of Safety and Efficiency of Afalaza in Patients With Symptoms of Benign Prostatic Hyperplasia and Risk of Progression", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Benign Prostatic Hyperplasia", 
        "condition_browse": {
            "mesh_term": [
                "Prostatic Hyperplasia", 
                "Hyperplasia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male patients 45 to 60 y.o. inclusive with a documented diagnosis of Benign prostatic\n             hyperplasia.\n\n          2. Lower urinary tract symptoms having been experienced for 3 months and longer.\n\n          3. Total IPSS score (International Prostate Symptome Score) of 8 to 15.\n\n          4. Prostate volume of more than 30 cm3.\n\n          5. Maximal urinary flow rate of 10-15 mL/sec.\n\n          6. Micturition volume of 125-350 mL.\n\n          7. Residual volume of less than 100 mL.\n\n          8. Serum PSA level of less than 4 ng/mL.\n\n          9. Use of and compliance with contraceptive methods during the trial and for 30 days\n             upon completion of participation in the trial.\n\n         10. Presence of the patient's information sheet (informed consent form) for participation\n             in the clinical trial.\n\n        Exclusion Criteria:\n\n          1. Invasive therapies for BPH including a transurethral prostatic resection,\n             thermotherapy, microwave therapy, transurethral needle ablation, stenting , etc.\n\n          2. Malignant oncological disease of the urogenital system as well as malignancies of any\n             other localization during last 5 years.\n\n          3. Acute urinary retention within 3 months before inclusion in the trial.\n\n          4. Neurogenic dysfunctions and bladder ears.\n\n          5. Urinary stone disease.\n\n          6. Urethral stricture, bladder neck sclerosis.\n\n          7. History of operative aids for pelvic organs.\n\n          8. Urogenital infections in the phase of active inflammation.\n\n          9. Systematic administration of agents exhibiting effects on bladder function and urine\n             production.\n\n         10. Exacerbation or decompensation of chronic diseases affecting the possibility of\n             patients to participate in the clinical trial, including severe concurrent\n             cardiovascular conditions and disorders of the nervous system, renal and hepatic\n             insufficiency.\n\n         11. History of administration of testosterone 5-alpha-reductase inhibitors (finasteride,\n             dutasteride).\n\n         12. History of polyvalent allergy.\n\n         13. Allergy/intolerance to any component of drug agents used in the therapy.\n\n         14. Malabsorption syndrome, including congenital or acquired lactase or other\n             disaccharidase deficiency.\n\n         15. Administration of drugs specified as \"Prohibited concomitant therapy\", within 3\n             months before enrollment.\n\n         16. Exacerbation or decompensation of chronic diseases affecting the possibility of\n             patients to participate in the clinical trial.\n\n         17. Drug and alcohol consumption (over 2 alc. units daily), mental diseases. Legal\n             incapacity or limited legal capacity.\n\n         18. Legal incapacitation or limited legal capacity.\n\n         19. Patients, who, in the investigator's opinion, will fail to observe the requirements\n             during the trial or adhere to the studied drug administration procedure.\n\n         20. Participation in other clinical trials within 3 months before enrolment in this\n             trial.\n\n         21. Presence of other factors, complicating the patient's participation in the trial\n             (e.g., planned lengthy business and other trips).\n\n         22. A patient is a part of the center's research staff, taking a direct part in the\n             trial, or an immediate family member of the investigator. Immediate family members\n             are defined as spouses, parents, children or siblings, regardless of whether full\n             blood or adopted.\n\n         23. The patient is employed with Scientific Production Firm Materia Medica Holding LLC,\n             i.e. is the company's employee, part-time employee under contract, or appointed\n             official in charge of the trial, or their immediate family."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "45 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 25, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01716104", 
            "org_study_id": "MMH-AZ-001"
        }, 
        "intervention": [
            {
                "arm_group_label": "Afalaza (2 tablets twice a day)", 
                "description": "Safety and Efficiency", 
                "intervention_name": "Afalaza", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo (2 tablets twice a day)", 
                "description": "Safety and Efficiency", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 23, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "Andrey Vinarov, Prof"
                }, 
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation", 
                        "zip": "119991"
                    }, 
                    "name": "The State Budget Educational institution of High Professional Training I.M. Sechenov First Moscow State Medical University of Ministry of Health Care and Social Development of the Russian Federation, Department of Urology"
                }, 
                "investigator": {
                    "last_name": "Andrey Vinarov, Prof", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Vladimir Avdoshin, Prof"
                }, 
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation", 
                        "zip": "117198"
                    }, 
                    "name": "The Federal State Budget Educational institution of High Professional Training \"Peoples' Friendship University of Russia\", Department of Urology and Operative Nephrology"
                }, 
                "investigator": {
                    "last_name": "Vladimir Avdoshin, Prof", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Alexey Kornev, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation", 
                        "zip": "109472"
                    }, 
                    "name": "The State Budget Health Care institution of Moscow the City \"Hospital for veterans of wars No. 2 of the Administration of Health Care of Moscow City\""
                }, 
                "investigator": {
                    "last_name": "Alexey Kornev, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Ekaterina Korshunova, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation", 
                        "zip": "115419"
                    }, 
                    "name": "The State Budget Health Care institution of Moscow the City \"Specialized clinical (neuro-psychiatric) hospital No. 8 n.a. Z.P. Solovyov - ''Clinic of neuroses\" of the Administration of Health Care of Moscow City"
                }, 
                "investigator": {
                    "last_name": "Ekaterina Korshunova, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Vadim Surikov, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation", 
                        "zip": "129090"
                    }, 
                    "name": "The Federal State Budget institution \"Polyclinic \u2116 3\" of Affairs Management Department of the President of the Russian Federation"
                }, 
                "investigator": {
                    "last_name": "Vadim Surikov, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Igor Aboyan, Prof"
                }, 
                "facility": {
                    "address": {
                        "city": "Rostov-on-Don", 
                        "country": "Russian Federation", 
                        "zip": "344011"
                    }, 
                    "name": "Municipal Treatment-and-Prophylactic Health Care institution Clinical Diagnostic Centre \"Zdorovie\""
                }, 
                "investigator": {
                    "last_name": "Igor Aboyan, Prof", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Vladimir Heifetz, Prof"
                }, 
                "facility": {
                    "address": {
                        "city": "St. Petersburg", 
                        "country": "Russian Federation", 
                        "zip": "199178"
                    }, 
                    "name": "Limited Liability Company \"Hospital OrCli\""
                }, 
                "investigator": {
                    "last_name": "Vladimir Heifetz, Prof", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Sergey Petrov, Prof"
                }, 
                "facility": {
                    "address": {
                        "city": "St. Petersburg", 
                        "country": "Russian Federation", 
                        "zip": "194044"
                    }, 
                    "name": "The Federal State institution \"All-Russian center of emergency and radiation medicine n.a. A.M. Nikiforov\" of the Ministry of the Russian Federation for Affairs of civil defence, emergencies and elimination of consequences of natural disasters"
                }, 
                "investigator": {
                    "last_name": "Sergey Petrov, Prof", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Andrey Gorelov, Prof"
                }, 
                "facility": {
                    "address": {
                        "city": "St. Petersburg", 
                        "country": "Russian Federation", 
                        "zip": "199106"
                    }, 
                    "name": "Saint-Petersburg State Budget Health Care institution \"Pokrovsky city hospital\""
                }, 
                "investigator": {
                    "last_name": "Andrey Gorelov, Prof", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Russian Federation"
        }, 
        "number_of_arms": "2", 
        "official_title": "Multicentric Double-blind Placebo-controlled Randomized Parallel-group Clinical Trial of Safety and Efficiency of Afalaza in Patients With Symptoms of Benign Prostatic Hyperplasia and Risk of Progression", 
        "overall_contact": {
            "email": "PutilovskiyMA@materiamedica.ru", 
            "last_name": "Mikhail Putilovskiy, MD", 
            "phone": "+74957836804", 
            "phone_ext": "302"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Russia: Ministry of Health of the Russian Federation", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in total IPSS scores (International Prostate Symptome Score) after 1, 3, 6 and 12 months compared to baseline.", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01716104"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Dynamics of irritative symptoms evaluated by IPSS (International Prostate Symptome Score) after 1, 3, 6 and 12 months compared to baseline", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "source": "Materia Medica Holding", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Materia Medica Holding", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}